APRE - Why Is Precision Oncology-Focused Aprea Therapeutics Stock Trading Higher On Monday? | Benzinga
Monday, Aprea Therapeutics Inc (NASDAQ:APRE) announced that the FDA has cleared its Investigational New Drug (IND) application for APR-1051.
“APR-1051 is a next-generation inhibitor of WEE1 kinase, and based on its unique characteristics, we believe it will be best in class,” said Oren Gilad, President and CEO of Aprea.
“We look forward to evaluating therapeutic activity in patients, focusing on Cyclin E overexpressing cancers, including ovarian and breast cancers,” Gilad added.
Clearance of ...